Andrea A. Lania

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.

Journal: Frontiers in endocrinology
Published: May 13, 2026

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.

Journal: Current oncology (Toronto, Ont.)
Published: November 15, 2025

Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis.

Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis.

Journal: Frontiers in endocrinology
Published: November 11, 2025

Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey.

Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey.

Journal: Frontiers in endocrinology
Published: August 22, 2025

Management of type I gastric-neuroendocrine tumors: the less the better?

Management of type I gastric-neuroendocrine tumors: the less the better?

Journal: Frontiers in endocrinology
Published: July 15, 2025

Neuroendocrine tumors in patients with inflammatory bowel disease: a case series.

Neuroendocrine tumors in patients with inflammatory bowel disease: a case series.

Journal: Endocrine
Published: June 24, 2025

Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study.

Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study.

Journal: Endocrine-related cancer
Published: May 01, 2025

Improvement of medication adherence in osteoporosis through telemedicine combined with email: a patient-reported experience and outcome measure-based prospective study.

Improvement of medication adherence in osteoporosis through telemedicine combined with email: a patient-reported experience and outcome measure-based prospective study.

Journal: BMJ health & care informatics
Published: November 01, 2024

Could low prolactin levels after radiotherapy predict the onset of hypopituitarism?

Could low prolactin levels after radiotherapy predict the onset of hypopituitarism?

Journal: Reviews in endocrine & metabolic disorders
Published: August 08, 2024

Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.

Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.

Journal: Diagnostics (Basel, Switzerland)
Published: June 05, 2024

Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.

Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.

Journal: Cancers
Published: July 06, 2023

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.

Journal: Cancers
Published: April 17, 2023
Showing 1-12 of 20

Last Updated: 09/26/2026